TRVI — TREVI THERAPEUTICS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying TRVI?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 1 tracked investors who changed their TRVI position last quarter, 0 bought and 1 sold (0% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 57/100 in a Contraction regime).
- +3 tracked investors reported holding TRVI at their latest filing
- +Macro Health is 57/100 in a Contraction regime — historically acceptable for this sectorsource
- −1 tracked investor reduced or exited last quarter (1 reduced, 0 sold out)
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/6/2026.
About TREVI THERAPEUTICS INC (TRVI)
TREVI THERAPEUTICS INC (TRVI) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Andreas Halvorsen (Viking Global Investors), valued at $47M. Across recent filings, tracked investors recorded 1 new positions, 1 increased, 4 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in TRVI
How many top investors track TRVI
A small number of top investors own this.
TRVI Ownership Composition
How TREVI THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.
- Other86.8%
- Multi-Strategy / Quant9.1%
- Macro4.2%
Tracked investors currently reporting TRVI
2 tracked investors have since exited this position — listed separately below.
- Andreas HalvorsenJun 30, 2026Viking Global InvestorsShares1.5MValue$28.8M% Portfolio0.08%
- Ken GriffinJun 30, 2026Citadel AdvisorsShares161.5KValue$3M% Portfolio0.00%
- Paul Tudor JonesJun 30, 2026Tudor Investment CorpShares74KValue$1.4M% Portfolio0.00%
Previously held TRVI
These investors reported TRVI in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.
| Investor | Firm | Last reported shares | Value then | Last held |
|---|---|---|---|---|
| Steve Cohen | Point72 Asset Management | 1M | $12.5M | Dec 31, 2025 |
| Izzy Englander | Millennium Management | 571K | $6.8M | Mar 31, 2026 |
Recent activity
- Unchanged$18.1M(0.00%)Feb 14, 2025
- Reduced$20.3M(-26.64%)May 15, 2025
- Reduced$8.4M(-52.20%)Aug 14, 2025
- Increased$46.9M(232.40%)Nov 14, 2025
- Reduced$40M(-37.63%)Feb 17, 2026
- Unchanged$38.2M(0.00%)May 15, 2026
- Reduced$28.8M(-51.71%)Aug 14, 2026
- $14.7MNov 14, 2024
Frequently asked questions
- How many institutional investors hold TRVI?
- 3 tracked institutional investors disclosed a position in TRVI (TREVI THERAPEUTICS INC) in their most recent 13F filing.
- Who is the largest institutional holder of TRVI?
- Andreas Halvorsen, Viking Global Investors, holds the largest disclosed position in TRVI, valued at $47M.
- Did institutional ownership of TRVI increase or decrease?
- Across recent 13F filings, tracked investors recorded 1 new positions, 1 increased, 4 reduced, and 0 fully exited TRVI.
- Where does this TRVI ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.